（来源：淘金ETF） 2026年1月20日，国家疾控局联合国家发改委、财政部、国家卫生健康委等六部委正式印发《疾病预防 控制领域强基实施方案》（国疾控规财发〔2026〕3号），锚定2027、2030两大阶段目标，以"基础补短 板、设备标准化、数智化升级"为核心抓手，全面部署疾控体系强基工程；1月27日公开发布，政策红利 正式释放，万亿级公共卫生设备市场需求被激活，医疗器械板块迎来政策驱动下的设备更新与产业升级 黄金机遇期。 核心痛点亟待破解，政策精准施策 当前我国疾控体系仍面临"资源不均、设备滞后、数智薄弱"三大痛点——基层医疗机构基础诊疗设备普 及率，大量设备超期服役，中西部县域疾控设备达标率低；疾控资源80%集中在城市高端医疗机构，县 域及乡镇疾控"硬件""软件"双重薄弱；传统监测预警、流调溯源依赖人工，数智化应用未覆盖基层末 梢。与此同时，人口老龄化推升慢性病防控压力，公共卫生应急响应对设备标准化、数智化的要求持续 升级，筑牢基层疾控网底成为"健康中国"建设的关键一环。本次六部委从印发到公开发布的密集动作， 正是瞄准这些核心痛点的精准施策，既是落实中央经济工作会议"医疗卫生强基工程"的关键举措，更是 为 ...

1月27日，A股市场整体上涨。 截至收盘，上证指数收报4139.9点，上涨0.18%；深证成指收报14329.91点，上涨0.09%；创业板指收报3342.6点，上涨0.71%。两市合计成交 28949.81亿元，较上一交易日减少3532.21亿元。 1. 两市主力资金净流出超410亿元 今日沪深两市主力资金开盘净流出373.34亿元，尾盘净流入41.39亿元，两市全天主力资金净流出414.34亿元。 | | | 沪深两市最近五个交易日主力资金流向情况 (亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | 尾盘净流入 | 超大单净买入 | | 2026- 1- 27 | - 414. 34 | -373. 34 | 41. 39 | - 173. 55 | | 2026- 1- 26 | - 757. 10 | -324. 59 | - 15. 61 | - 496. 92 | | 2026- 1-23 | - 41. 67 | - 83. 56 | 58. 37 | 119. 93 | | 2026- 1- 22 | - 104. ...

Core Viewpoint - The healthcare index (980016) closed at 6173.05 points, down 0.98%, with a trading volume of 32.835 billion yuan and a turnover rate of 1.29% [1] Group 1: Index Performance - Among the index constituents, 11 stocks rose while 39 stocks fell, with Sangfor Technologies leading the gainers at a 10.93% increase and Huahai Pharmaceutical leading the decliners with a 3.79% drop [1] - The top ten constituents of the healthcare index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 10.23%, 9.85%, and 8.23% [1] Group 2: Market Capitalization and Price Movements - WuXi AppTec has a market capitalization of 285.814 billion yuan, while Hengrui Medicine and Mindray Medical have market capitalizations of 379.648 billion yuan and 232.983 billion yuan, respectively [1] - The latest prices for the top ten constituents range from 11.12 yuan for Aier Eye Hospital to 192.16 yuan for Mindray Medical, with varying price changes [1] Group 3: Capital Flow - The net outflow of main funds from the healthcare index constituents totaled 1.252 billion yuan, while retail investors saw a net inflow of 1.093 billion yuan [1] - Detailed capital flow data indicates that Junshi Biosciences experienced a net inflow of 1.93 million yuan from main funds, while other companies like Dong'e Ejiao and Tigermed saw mixed capital flows [2]

Group 1 - The core point of the article highlights the recent trading activity of Mindray Medical, which saw a decline of 1.51% in its stock price, closing at 192.16 yuan [1] - A significant block trade occurred on January 27, with a total volume of 41,800 shares and a transaction value of 8.0415 million yuan, indicating a premium rate of 0.11% [1] - Over the past three months, Mindray Medical has recorded 13 block trades, with a cumulative transaction value of 172 million yuan [1] Group 2 - In the last five trading days, the stock has experienced a cumulative decline of 2.46%, with a net outflow of 232 million yuan from major funds [1]

Group 1 - The core transaction of Mindray Medical on January 27 involved a block trade of 41,800 shares, amounting to 8.0415 million yuan, with a transaction price of 192.38 yuan, reflecting a premium of 0.11% over the closing price of the day [2][3] - In the last three months, Mindray Medical has recorded a total of 13 block trades, with a cumulative transaction amount of 172 million yuan [2] - The closing price of Mindray Medical on the day of the transaction was 192.16 yuan, showing a decline of 1.51%, with a daily turnover rate of 0.79% and a total trading volume of 1.848 billion yuan [2] Group 2 - The latest margin financing balance for Mindray Medical is 4.137 billion yuan, which has increased by 154 million yuan over the past five days, representing a growth rate of 3.87% [3] - Mindray Medical was established on January 25, 1999, with a registered capital of 12.1244 billion yuan [3]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 买方营业部 (万元) | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2026-01-27 | 300760 | 迈瑞医疗 | 192.38 | 4.18 | 804.15 光大证券股份有限 | 光大证券股份有限 | | | | | | | 公司宁波柳汀街证 | 公司宁波柳汀街证 | | | | | | | 券营业部 | 券营业部 | 1月27日，迈瑞医疗大宗交易成交4.18万股，成交额804.15万元，占当日总成交额的0.43%，成交价 192.38元，较市场收盘价192.16元溢价0.11%。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The overall and weighted holdings of public funds in the pharmaceutical sector reached a new low since 2018 in Q4 2025, with the pharmaceutical heavy holdings accounting for 8.0% of all public funds, down 1.7 percentage points quarter-on-quarter [2][9] - The total scale of pharmaceutical funds in Q4 2025 was 394.6 billion yuan, a decrease of 9.2% from the previous quarter, with active pharmaceutical funds at 177.7 billion yuan, down 14% [20] - The proportion of passive pharmaceutical funds has increased significantly from 18% in Q1 2018 to 55% in Q4 2025, indicating a shift towards passive investment strategies in the sector [20] Fund Holdings Analysis - In Q4 2025, the pharmaceutical sector saw a decrease in active fund holdings, with active pharmaceutical funds accounting for 33% of the total pharmaceutical heavy holdings, up 2 percentage points, while non-pharmaceutical active funds accounted for 26%, down 5.1 percentage points [3][13] - The top five holdings by market value in public funds included Heng Rui Medicine (31.7 billion), WuXi AppTec (29.6 billion), and Innovent Biologics (16.6 billion) [6] - The top three increases in active fund holdings were for Tigermed (1.7 billion), Yimeng Biologics (1.4 billion), and CSPC Pharmaceutical Group (1.3 billion) [6] Sector-Specific Trends - The report highlights a shift in fund holdings towards innovative drugs and CXO services, while traditional Chinese medicine and high-value consumables are underweighted [6] - The report notes that the proportion of holdings in traditional Chinese medicine and biotech has increased, while holdings in BioPharma and CXO have decreased significantly [6][28] - The overall market value of holdings in the Bio-Tech sector reached 7.25% in Q4 2025, marking the highest level since Q1 2018, with active pharmaceutical funds holding 4.9% [28]

Core Viewpoint - The recent Nipah virus outbreak in India has led to increased attention and investment in the A-share pharmaceutical sector, with significant capital inflows into medical ETFs despite some declines in stock prices [1][3]. Group 1: Market Activity - The medical ETF (159929) experienced a drop of over 1% today, following a previous day of gains, but attracted 64 million yuan in capital [1]. - Over the past 10 days, the ETF has seen net inflows for 9 days, accumulating nearly 300 million yuan [1]. - Trading activity remains robust, with intraday trading volume exceeding 120 million yuan [1]. Group 2: Nipah Virus Research - The Nipah virus outbreak in West Bengal, India, has resulted in deaths and the isolation of close contacts [3]. - A significant research study published in the journal Emerging Microbes & Infections confirms that the oral nucleoside drug VV116 shows promising antiviral activity against the Nipah virus, providing new hope for treatment and prevention [3]. Group 3: Company Updates - Sanofi's (三生国健) 2025 annual performance forecast indicates a net profit of approximately 2.9 billion yuan, reflecting a year-on-year increase of 311.35%, driven by a collaboration with Pfizer [4]. - Junshi Biosciences (君实生物) has completed the issuance of its first phase of technology innovation bonds for 2026, totaling 1 billion yuan, aimed at supporting drug research and development [4]. Group 4: Sector Trends - The pharmaceutical industry is expected to benefit from a favorable investment environment and policy support, particularly for innovative drugs and technologies [6][8]. - The medical manufacturing sector has shown a slight increase in industrial value added, while revenue and profit have seen minor declines [7]. - The healthcare expenditure in China has shown a year-on-year growth of 4.7% for the first 11 months of 2025, marking a recovery after two years of decline [7]. Group 5: Investment Strategies - Investment strategies for 2026 focus on innovation, international expansion, and marginal improvements in the pharmaceutical sector [8][9]. - Key areas of interest include innovative drugs, medical devices, and the integration of new technologies such as AI and brain-machine interfaces [8][9].

Core Viewpoint - The latest report indicates a mixed performance among the top ten holdings of the ChiNext 50 ETF (159949), with significant fluctuations in stock prices, reflecting the current market dynamics [1][3]. Group 1: Stock Performance - As of midday, the performance of the top ten holdings varied: Ningde Times fell by 0.89%, Zhongji Xuchuang rose by 5.61%, Xinyi Sheng increased by 4.28%, Dongfang Wealth dropped by 1.63%, and others showed similar fluctuations [1][3]. - The holdings and their respective market values are as follows: Ningde Times at approximately 6.59 billion yuan, Zhongji Xuchuang at about 3.65 billion yuan, and Xinyi Sheng at around 2.68 billion yuan, among others [1]. Group 2: Institutional Insights - China Galaxy Securities highlights that the demand for AI computing power, the upward cycle of storage chips, and the penetration of advanced packaging technology are driving the demand for semiconductor equipment, with strong growth expectations for the semiconductor equipment market by 2026 [1][3]. - Huaxi Securities suggests that, from a medium to long-term perspective, the current market is still in the middle of a "slow bull" trend, with recommendations to focus on sectors such as technology, chemicals, and high-growth industries like electronics and pharmaceuticals [1][3]. Group 3: ETF Performance - The ChiNext 50 ETF (159949) has provided a return of 35.67% over the past three years, outperforming its benchmark and ranking 528th among 1,633 similar products [2][4]. - The ETF is accessible for trading through stock accounts and linked funds, with recommendations for investors to adopt a systematic investment approach to mitigate short-term volatility [2][4].

证券日报网讯1月26日，迈瑞医疗（300760）在互动平台回答投资者提问时表示，当今数字化转型已成 为企业发展的核心驱动力。借助数字力量，迈瑞的业务链管理从供应商端至客户端，各环节均实现了协 同合作，更好地保障了产品生产、交付、服务的质量，为迈瑞医疗在全球市场的稳健发展筑牢根基。通 过数字化建设，公司实现了供应链业务全链路运营支撑，可更好地支持经营分析、现金流管理、运营结 果分析、预算管理、以及合规与风险管理流程的运转。公司的供应链驾驶舱整合了各个环节的数据，打 破信息孤岛，确保产品从物料供应到交付的每一环节都符合法规和质量要求。2024年，公司重点强化了 总部与各生产基地的数字化建设、以及海外工厂和仓库的系统对接。针对国内生产基地，新建砀山生产 基地实现了数字供应链系统基础生产业务的全覆盖，并完成了与南京生产基地的系统联通，实现多基地 的生产协同。武汉生产基地数字化系统也已完成并投入运行，支持高值医用耗材业务。在海外，公司启 动了欧洲生产基地数字化系统的本土化建设，打通了国内仓储与欧洲外仓系统，实现高效对接，强化了 区域成品交付能力。凭借坚实的信息化基础，公司继续扩大信息化系统覆盖的范围和深度，建设数字化 ...